

Adam C Yopp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5213724/publications.pdf>

Version: 2024-02-01

134
papers

6,422
citations

87888

38
h-index

74163

75
g-index

135
all docs

135
docs citations

135
times ranked

9840
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. <i>Nature Communications</i> , 2015, 6, 6744.	12.8	879
2	Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1706-1718.e1.	1.3	695
3	The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 325-334.	0.4	270
4	An Essential Mesenchymal Function for miR-143/145 in Intestinal Epithelial Regeneration. <i>Cell</i> , 2014, 157, 1104-1116.	28.9	188
5	An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 1196-1205.	7.3	188
6	Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome. <i>Annals of Surgical Oncology</i> , 2014, 21, 1287-1295.	1.5	182
7	Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer. <i>Cancer Cell</i> , 2017, 32, 574-589.e6.	16.8	172
8	Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease. <i>Cell</i> , 2019, 177, 608-621.e12.	28.9	167
9	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. <i>Future Oncology</i> , 2020, 16, 975-989.	2.4	136
10	Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 551-559.e1.	4.4	131
11	Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 875-884.	7.3	129
12	Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance. <i>American Journal of Medicine</i> , 2015, 128, 90.e1-90.e7.	1.5	128
13	Factors That Affect Accuracy of α -Fetoprotein Test in Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 870-877.	4.4	109
14	Invasive Carcinoma Arising in Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2011, 253, 968-974.	4.2	107
15	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 365.	4.3	102
16	Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. <i>American Journal of Medicine</i> , 2017, 130, 1099-1106.e1.	1.5	99
17	Minimally Invasive Versus Open Pancreaticoduodenectomy. <i>Annals of Surgery</i> , 2018, 268, 151-157.	4.2	97
18	Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. <i>Hepatology</i> , 2020, 72, 1654-1665.	7.3	93

#	ARTICLE	IF	CITATIONS
19	Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. <i>Gastroenterology</i> , 2018, 154, 1421-1434.	1.3	88
20	Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 791-798.e1.	4.4	86
21	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. <i>Annals of Surgical Oncology</i> , 2011, 18, 2192-2199.	1.5	76
22	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 134-141.	1.5	76
23	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. <i>Journal of the American College of Surgeons</i> , 2016, 222, 480-490.	0.5	71
24	Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling. <i>Nature Communications</i> , 2019, 10, 1473.	12.8	71
25	Robotic Versus Laparoscopic Pancreaticoduodenectomy: a NSQIP Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1784-1792.	1.7	68
26	Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2018, 4, 31.	7.1	60
27	Abbreviated protocol screening MRI vs. complete protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 415-425.	3.4	57
28	Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 242-248.e5.	4.4	57
29	Mice With Increased Numbers of Polyploid Hepatocytes Maintain Regenerative Capacity But Develop Fewer Hepatocellular Carcinomas Following Chronic Liver Injury. <i>Gastroenterology</i> , 2020, 158, 1698-1712.e14.	1.3	55
30	Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1561-1569.e4.	4.4	52
31	Robotic-assisted versus laparoscopic pancreaticoduodenectomy: oncological outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 2907-2913.	2.4	50
32	Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. <i>Gut</i> , 2021, 70, gutjnl-2020-321040.	12.1	48
33	Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1925-1932.e1.	4.4	46
34	Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 701-709.	3.7	45
35	CXCR4 Expression Predicts Patient Outcome and Recurrence Patterns after Hepatic Resection for Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2012, 19, 339-346.	1.5	43
36	Conversion of Minimally Invasive Distal Pancreatectomy: Predictors and Outcomes. <i>Annals of Surgical Oncology</i> , 2017, 24, 3725-3731.	1.5	43

#	ARTICLE	IF	CITATIONS
37	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. American Journal of Surgery, 2016, 211, 1106-1113.	1.8	42
38	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Annals of Surgical Oncology, 2016, 23, 126-133.	1.5	42
39	Medical Management of Hepatocellular Carcinoma. Journal of Oncology Practice, 2017, 13, 356-364.	2.5	42
40	Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma. Cancer, 2019, 125, 3428-3436.	4.1	41
41	Diagnostic Delays Are Common Among Patients With Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 543-549.	4.9	40
42	Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. Journal of Gastrointestinal Surgery, 2018, 22, 695-702.	1.7	40
43	Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012. Journal of Surgical Oncology, 2019, 119, 303-317.	1.7	40
44	Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis. American Journal of Gastroenterology, 2016, 111, 967-975.	0.4	39
45	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. Annals of Surgical Oncology, 2016, 23, 708-713.	1.5	38
46	Curative Surgical Resection of Adrenocortical Carcinoma. Annals of Surgery, 2017, 265, 197-204.	4.2	38
47	Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database. Journal of Surgical Oncology, 2018, 118, 21-30.	1.7	38
48	Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma. Cancer, 2018, 124, 743-751.	4.1	37
49	Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172.	1.7	36
50	Actual 10-year survivors following resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2016, 114, 971-976.	1.7	36
51	Adjuvant Therapy Is Associated With Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study. Annals of Surgical Oncology, 2018, 25, 1193-1201.	1.5	33
52	Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2022, 20, e267-e288.	4.4	32
53	A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology, 2016, 14, 295-300.	4.4	31
54	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med, 2021, 2, 836-850.e10.	4.4	31

#	ARTICLE	IF	CITATIONS
55	Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 352-362.	1.7	27
56	Management of hepatocellular in the United States. <i>Chinese Clinical Oncology</i> , 2017, 6, 21-21.	1.2	26
57	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. <i>Journal of the American College of Surgeons</i> , 2016, 223, 794-803.	0.5	24
58	Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1075-1082.	1.5	22
59	Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas. <i>World Journal of Gastrointestinal Surgery</i> , 2010, 2, 359.	1.5	22
60	Racial and Ethnic Disparities in Barriers to Care in Patients with Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1094-1096.e2.	4.4	22
61	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020, 25, e1837-e1845.	3.7	21
62	Hispanic/Latino Patients with Gastric Adenocarcinoma Have Distinct Molecular Profiles Including a High Rate of Germline <i>CDH1</i> Variants. <i>Cancer Research</i> , 2020, 80, 2114-2124.	0.9	21
63	Clinical Efficiency and Safety Outcomes of Virtual Care for Oncology Patients During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2021, 17, e1327-e1332.	2.9	20
64	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 2308-2315.	1.5	19
65	Primary Gastric Melanoma: Case Report of a Rare Malignancy. <i>Rare Tumors</i> , 2015, 7, 46-49.	0.6	18
66	Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. <i>Annals of Surgical Oncology</i> , 2016, 23, 583-591.	1.5	18
67	Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. <i>Targeted Oncology</i> , 2019, 14, 541-550.	3.6	18
68	Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?. <i>Digestive Diseases</i> , 2015, 33, 642-647.	1.9	17
69	The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?. <i>Cancers</i> , 2019, 11, 1441.	3.7	17
70	Redefining High-Volume Gastric Cancer Centers: The Impact of Operative Volume on Surgical Outcomes. <i>Annals of Surgical Oncology</i> , 2021, 28, 4839-4847.	1.5	17
71	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	1.3	17
72	Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. <i>Annals of Surgical Oncology</i> , 2020, 27, 1997-2006.	1.5	16

#	ARTICLE	IF	CITATIONS
73	Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient-Derived Xenograft Assays. <i>Hepatology</i> , 2020, 72, 1085-1101.	7.3	16
74	Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1284-1290.	4.4	15
75	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-Term Survival. <i>World Journal of Surgery</i> , 2016, 40, 706-714.	1.6	15
76	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. <i>Annals of Surgical Oncology</i> , 2018, 25, 520-527.	1.5	15
77	Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1091-1093.e3.	4.4	15
78	Advances in Local and Systemic Therapies for Hepatocellular Cancer. <i>Current Oncology Reports</i> , 2016, 18, 9.	4.0	14
79	Current Pattern of Use and Impact of Pringle Maneuver in Liver Resections in the United States. <i>Journal of Surgical Research</i> , 2019, 239, 253-260.	1.6	14
80	Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1387-1395.	0.8	14
81	Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2021, 41, 001-008.	3.6	14
82	Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1815-1827.	1.7	13
83	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. <i>American Surgeon</i> , 2017, 83, 761-768.	0.8	12
84	Neuroendocrine Tumors in Meckel's Diverticulum: Recommendation for Lymphadenectomy Regardless of Tumor Size Based on the NCDB Experience. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 679-685.	1.7	12
85	Predictors and outcomes of converted minimally invasive pancreaticoduodenectomy: a propensity score matched analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 544-550.	2.4	12
86	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1157-e1169.	4.4	12
87	Nomogram to predict non-home discharge following pancreaticoduodenectomy in a national cohort of patients. <i>Hpb</i> , 2017, 19, 1037-1045.	0.3	11
88	Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 2080-2087.	1.7	11
89	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. <i>Surgery</i> , 2020, 167, 352-357.	1.9	11
90	Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. <i>Annals of Surgical Oncology</i> , 2021, 28, 6551-6561.	1.5	11

#	ARTICLE	IF	CITATIONS
91	Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study. <i>Cancer</i> , 2018, 124, 1122-1131.	4.1	10
92	Inaccurate Clinical Stage Is Common for Gastric Adenocarcinoma and Is Associated with Undertreatment and Worse Outcomes. <i>Annals of Surgical Oncology</i> , 2021, 28, 2831-2843.	1.5	10
93	Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study. <i>Hpb</i> , 2021, 23, 422-433.	0.3	10
94	Machine Learning Improves Prediction Over Logistic Regression on Resected Colon Cancer Patients. <i>Journal of Surgical Research</i> , 2022, 275, 181-193.	1.6	10
95	Socioeconomic and racial/ethnic disparities in receipt of palliative care among patients with metastatic hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 124, 1365-1372.	1.7	9
96	Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative. <i>Surgical Oncology</i> , 2020, 35, 120-125.	1.6	8
97	Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. <i>Journal of Surgical Oncology</i> , 2021, 123, 407-415.	1.7	8
98	High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	8
99	Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2379-2388.e6.	4.4	7
100	Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 1929-1936.	1.5	7
101	Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis. <i>Hpb</i> , 2021, 23, 868-876.	0.3	7
102	Epithelial to Mesenchymal Transition Expression Profiles as Predictive Biomarkers of Recurrence Following Resection of HCC: Implications for Current Clinical Use and Future Stratification for Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3723-3724.	1.5	6
103	The prognostic significance of adrenocortical carcinomas identified incidentally. <i>Journal of Surgical Oncology</i> , 2018, 118, 1155-1162.	1.7	6
104	Surgical resection of early stage hepatocellular carcinoma improves patient survival at safety net hospitals. <i>Journal of Surgical Oncology</i> , 2021, 123, 963-969.	1.7	6
105	Disparities in Guideline-Concordant Treatment and Survival Among Border County Residents With Gastric Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e748-e758.	2.9	6
106	Percutaneous cholecystostomy: the challenges of cohort analysis. <i>Journal of Surgical Research</i> , 2014, 190, 417-418.	1.6	5
107	Adjuvant Therapy is Associated with Improved Survival in pT1N1 Gastric Cancer in a Heterogeneous Western Patient Population. <i>Annals of Surgical Oncology</i> , 2019, 26, 167-176.	1.5	5
108	The presentation of Hispanic gastric cancer patients varies by location of patient ancestry. <i>Journal of Surgical Oncology</i> , 2021, 124, 1051-1059.	1.7	5

#	ARTICLE	IF	CITATIONS
109	Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population. <i>Annals of Surgical Oncology</i> , 2022, 29, 5488-5497.	1.5	5
110	Conversion Chemotherapy for Unresectable Colorectal Liver Metastases: Are We Making a Difference?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 160-167.	0.5	4
111	The Evolving Landscape of Hepatocellular Carcinoma. <i>American Surgeon</i> , 2020, 86, 865-872.	0.8	4
112	Comparison of radiofrequency and microwave ablation and identification of risk factors for primary treatment failure and local progression. <i>Clinical Imaging</i> , 2020, 67, 146-151.	1.5	4
113	Surgical resection of early stage hepatocellular carcinoma: balancing tumor biology with the host liver. <i>Chinese Clinical Oncology</i> , 2021, 10, 5-5.	1.2	4
114	Treatment and Survival Disparities of Colon Cancer in the Texas-Mexico Border Population: Cancer Disparities in Border Population. <i>Journal of Surgical Research</i> , 2021, 267, 432-442.	1.6	4
115	Nativity Status is an Important Social Determinant of Health for Hispanic Patients with Gastric Cancer in Texas. <i>Annals of Surgical Oncology</i> , 2022, 29, 3113-3121.	1.5	4
116	Reply. <i>Hepatology</i> , 2017, 66, 1002-1003.	7.3	3
117	Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population. <i>Journal of Translational Medicine</i> , 2022, 20, 116.	4.4	3
118	Preface. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, xv-xvii.	1.5	2
119	Laparoscopic liver resection for hepatocellular carcinoma: Indications and role. <i>Clinical Liver Disease</i> , 2012, 1, 206-208.	2.1	2
120	Hepatocellular Carcinoma Surveillance: All Cirrhotic Patients May Not Be Equal. <i>Gastroenterology</i> , 2012, 143, 1393-1395.	1.3	2
121	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 2154-2161.	1.7	2
122	Expansion of Criteria for Liver Transplantation in Hepatocellular Carcinoma: Better Patient Selection or a Slippery Slope?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1758-1760.	1.5	2
123	LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. <i>Abdominal Radiology</i> , 2021, 46, 3708-3716.	2.1	2
124	Does Surveillance for Hepatocellular Carcinoma Benefit Patients With Compensated Cirrhosis?. <i>Gastroenterology</i> , 2014, 147, 935-936.	1.3	1
125	Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 756-758.	4.4	1
126	Association of the establishment of multidisciplinary (MDC) hepatocellular carcinoma (HCC) clinic with clinical outcome.. <i>Journal of Clinical Oncology</i> , 2013, 31, 332-332.	1.6	1

#	ARTICLE	IF	CITATIONS
127	Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases: Making a Comeback?. Current Colorectal Cancer Reports, 2015, 11, 231-240.	0.5	0
128	Hepatocellular carcinoma: How can we move from racial/ethnic disparities to a model of health equity?. Cancer, 2016, 122, 2454-2456.	4.1	0
129	Commentary: Liver regeneration after major hepatectomy: Impact of body mass index. Surgery, 2016, 160, 92-93.	1.9	0
130	Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma. Current Hepatology Reports, 2017, 16, 146-151.	0.9	0
131	ASO Author Reflections: Use of Retrospective Administrative Datasets in Rare Cancer Subtypes to Determine the Efficacy of Adjuvant Therapy. Annals of Surgical Oncology, 2018, 25, 798-799.	1.5	0
132	Hospital variation in use of prophylactic drains following hepatectomy. Hpb, 2020, 22, 1471-1479.	0.3	0
133	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. VideoEndocrinology, 2018, 5, .	0.1	0
134	ASO Visual Abstract: Nativity Status is an Important Social Determinant of Health for Hispanic Patients with Gastric Cancer in Texas. Annals of Surgical Oncology, 2022, , .	1.5	0